Skip to content
TheChatArchiveThe Chat Archive
Grok 4.1 Fast· xaiHugging Face Frontier Reasoning Traces

Summarize stroke care: FAST recognition, imaging choices, tPA/tenecteplase criteria,…

  1. User

    Summarize stroke care: FAST recognition, imaging choices, tPA/tenecteplase criteria, thrombectomy, BP management, secondary prevention, rehab, and follow-up; include time windows.

  2. Assistant

    Stroke Care Summary (Acute Ischemic Stroke Focus)

    1. Recognition: FAST

    • Face drooping (smile asymmetry)
    • Arm weakness (hold arms up; one drifts)
    • Speech difficulty (slurred/repeating)
    • Time: Call 911 immediately (last known well = symptom onset or last normal)
    • Goal: Door-to-needle <60 min; door-to-groin <90 min.

    2. Imaging Choices

    • First-line: Non-contrast CT head (NCCT) to exclude hemorrhage/ICH (within 20 min of arrival).
    • Vascular: CT angiography (CTA) head/neck for large vessel occlusion (LVO; e.g., ICA/M1 MCA).
    • Advanced (extended windows): CT perfusion (CTP) or MRI perfusion/diffusion for salvageable tissue (mismatch).
    • Avoid MRI first unless CT unavailable (delays treatment).

    3. IV Thrombolysis: tPA (Alteplase) / Tenecteplase Criteria

    • Time windows:
      AgentWindowDose
      tPA0-3h (all); 3-4.5h (select)0.9 mg/kg IV (max 90 mg; 10% bolus, rest 1h)
      Tenecteplase0-4.5h (off-label/emerging; EXTEND-IA TNK trials)0.25 mg/kg single bolus (max 25 mg)
    • Inclusion: Age ≥18, NIHSS ≥4 (or disabling symptoms), last known well within window.
    • Key exclusions: ICH on CT, BP >185/110 (uncontrolled), recent major surgery/trauma (<3 mo), glucose <50/>400, seizure at onset, coagulopathy (INR >1.7, platelets <100k).
    • Combo: Thrombolysis + thrombectomy if LVO.

    4. Endovascular Thrombectomy

    • Indications: LVO (ASPECTS ≥6), NIHSS ≥6.
    • Time windows:
      WindowCriteria
      0-6hAll eligible (MR CLEAN, ESCAPE)
      6-24hPerfusion mismatch (DAWN: core <70mL; DEFUSE3: core <30mL + mismatch)
    • Technique: Stent retriever/aspiration; post-procedure antiplatelet if stented.

    5. BP Management

    • Pre-thrombolysis: <185/110 mmHg (labetalol/nicardipine).
    • Post-thrombolysis (0-24h): <180/105 mmHg.
    • No thrombolysis/thrombectomy: Permissive HTN (<220/120 mmHg).
    • Post-24h: Target <140/90 mmHg long-term (start oral agents: ACEi, thiazide).

    6. Secondary Prevention

    • Antiplatelet: Aspirin 160-325 mg x1 (within 48h), then 81 mg daily; or DAPT (aspirin + clopidogrel 21 days) for minor/non-cardioembolic.
    • Anticoag: If AFib (DOAC preferred; start 3-14 days post-stroke based on size).
    • Lipids: High-intensity statin (atorva 40-80 mg) target LDL <70 mg/dL.
    • Other: Glycemic control (HbA1c <7%), smoking cessation, lifestyle (Mediterranean diet, exercise).

    7. Rehabilitation

    • Start early (within 24-48h if stable): Multidisciplinary (PT/OT/speech/swallow screen).
    • Intensity: 3h/day, 5 days/wk; constraint-induced movement therapy for upper limb.
    • Complications: DVT prophylaxis, aspiration pneumonia prevention.

    8. Follow-up

    • Discharge: 3-7 days; MRI/TTE/echo/Holter for etiology.
    • Outpatient: 1-2 wks (wound check if craniotomy), 1-3 mo (NIHSS/mRS, risk factor titration), then q3-6 mo.
    • Long-term: Annual neurovascular imaging if high-risk; depression screen.

    Guidelines: AHA/ASA 2019/2023 updates; individualize per patient (e.g., wake-up strokes via perfusion).

Responses were produced in different, uncontrolled contexts (system prompts, settings, prior turns). This is not a benchmark.